Clinical management of rising prostate-specific antigen after radical retropubic prostatectomy

J. Kellogg Parsons; Alan W. Partin

Clinical management of rising prostate-specific antigen after radical retropubic prostatectomy

J. Kellogg Parsons, Alan W. Partin

School of Medicine

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Introduction Approximately 40% of men diagnosed with prostate cancer will undergo radical prostatectomy.1 Of these, 15% to 46% will manifest an isolated, asymptomatic rise in postoperative PSA within 15 years. This phenomenon is referred to as biochemical recurrence. Since an estimated 75,000 radical prostatectomies are performed annually in the US, biochemical recurrence after prostatectomy represents a healthcare issue of considerable magnitude, affecting several thousand men each year.2.

Original language	English (US)
Title of host publication	Treatment Methods for Early and Advanced Prostate Cancer
Publisher	CRC Press
Pages	107-113
Number of pages	7
ISBN (Electronic)	9780203091432
ISBN (Print)	0415458935, 9780415458931
State	Published - Jan 1 2008

ASJC Scopus subject areas

General Medicine

Cite this

@inbook{0aa8b74292db464e9709914d1d810c05,

title = "Clinical management of rising prostate-specific antigen after radical retropubic prostatectomy",

abstract = "Introduction Approximately 40% of men diagnosed with prostate cancer will undergo radical prostatectomy.1 Of these, 15% to 46% will manifest an isolated, asymptomatic rise in postoperative PSA within 15 years. This phenomenon is referred to as biochemical recurrence. Since an estimated 75,000 radical prostatectomies are performed annually in the US, biochemical recurrence after prostatectomy represents a healthcare issue of considerable magnitude, affecting several thousand men each year.2.",

author = "Parsons, {J. Kellogg} and Partin, {Alan W.}",

note = "Publisher Copyright: {\textcopyright} 2008 Informa UK Ltd.",

year = "2008",

month = jan,

day = "1",

language = "English (US)",

isbn = "0415458935",

pages = "107--113",

booktitle = "Treatment Methods for Early and Advanced Prostate Cancer",

publisher = "CRC Press",

address = "United States",

}

TY - CHAP

T1 - Clinical management of rising prostate-specific antigen after radical retropubic prostatectomy

AU - Parsons, J. Kellogg

AU - Partin, Alan W.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Introduction Approximately 40% of men diagnosed with prostate cancer will undergo radical prostatectomy.1 Of these, 15% to 46% will manifest an isolated, asymptomatic rise in postoperative PSA within 15 years. This phenomenon is referred to as biochemical recurrence. Since an estimated 75,000 radical prostatectomies are performed annually in the US, biochemical recurrence after prostatectomy represents a healthcare issue of considerable magnitude, affecting several thousand men each year.2.

AB - Introduction Approximately 40% of men diagnosed with prostate cancer will undergo radical prostatectomy.1 Of these, 15% to 46% will manifest an isolated, asymptomatic rise in postoperative PSA within 15 years. This phenomenon is referred to as biochemical recurrence. Since an estimated 75,000 radical prostatectomies are performed annually in the US, biochemical recurrence after prostatectomy represents a healthcare issue of considerable magnitude, affecting several thousand men each year.2.

UR - http://www.scopus.com/inward/record.url?scp=85056536311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056536311&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056536311

SN - 0415458935

SN - 9780415458931

SP - 107

EP - 113

BT - Treatment Methods for Early and Advanced Prostate Cancer

PB - CRC Press

ER -

Clinical management of rising prostate-specific antigen after radical retropubic prostatectomy

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this